About Us  Contact Us  Donate                     

logo ogcc

   button donate  button share your survivor story  button volunteer

Intraperitoneal chemotherapy in ovarian cancer

Long-term findings from two randomized trials demonstrated that intraperitoneal (IP) chemotherapy significantly improved survival compared with intravenous (IV) therapy. The combined analysis of the GOG-172 and GOG-114 trials showed that patients treated with IP chemotherapy experienced a 16% reduction in the risk of progression compared with IV therapy. Additionally, IP chemotherapy led to a median overall survival (OS) of 62 months compared with 51 months for IV therapy.

Thank you to our supporters!

supporter logo flt    supporter logo ocrfa     supporter logo potomac at avenel